CytomX Therapeutics Inc [NASDAQ: CTMX] stock went on an upward path that rose over 12.84% on Tuesday, amounting to a one-week price increase of more than 28.08%.
Over the last 12 months, CTMX stock dropped by -12.77%. The one-year CytomX Therapeutics Inc stock forecast points to a potential upside of 76.75. The average equity rating for CTMX stock is currently 2.00, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $96.26 million, with 78.23 million shares outstanding and 76.93 million shares in the current float. Compared to the average trading volume of 845.16K shares, CTMX stock reached a trading volume of 12654881 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on CytomX Therapeutics Inc [CTMX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for CTMX shares is $5.29 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on CTMX stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Piper Sandler have made an estimate for CytomX Therapeutics Inc shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on May 28, 2024. The new note on the price target was released on May 09, 2024, representing the official price target for CytomX Therapeutics Inc stock. Previously, the target price had yet another raise from $2.50 to $8, while Jefferies kept a Buy rating on CTMX stock.
The Average True Range (ATR) for CytomX Therapeutics Inc is set at 0.09, with the Price to Sales ratio for CTMX stock in the period of the last 12 months amounting to 0.76.
CTMX Stock Performance Analysis:
CytomX Therapeutics Inc [CTMX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 28.08. With this latest performance, CTMX shares gained by 17.14% in over the last four-week period, additionally sinking by -26.79% over the last 6 months – not to mention a drop of -12.77% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CTMX stock in for the last two-week period is set at 69.90, with the RSI for the last a single of trading hit 79.26, and the three-weeks RSI is set at 63.19 for CytomX Therapeutics Inc [CTMX]. The present Moving Average for the last 50 days of trading for this stock 1.0666, while it was recorded at 1.0840 for the last single week of trading, and 1.5753 for the last 200 days.
Insight into CytomX Therapeutics Inc Fundamentals:
CytomX Therapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.04 and a Current Ratio set at 1.04.
CTMX Stock EPS
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for CTMX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for CytomX Therapeutics Inc go to -0.90%.
CytomX Therapeutics Inc [CTMX] Institutonal Ownership Details
There are presently around $65.62%, or 66.29%% of CTMX stock, in the hands of institutional investors. The top three institutional holders of CTMX stocks are: TANG CAPITAL MANAGEMENT LLC with ownership of 7.79 million shares, which is approximately 9.4989%. JANUS HENDERSON GROUP PLC, holding 6.3 million shares of the stock with an approximate value of $$7.72 million in CTMX stocks shares; and JANUS HENDERSON GROUP PLC, currently with $$6.38 million in CTMX stock with ownership which is approximately 6.3739%.
